GLAXOSMITHKLINE PLC Form 6-K May 03, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending May 2012

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

_

GlaxoSmithKline plc - Result of AGM

GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders.

GlaxoSmithKline AGM Poll Results

The following table shows the votes cast for each resolution:

| Resolution | | Total votes % for* | Total votes against | % | Total votes cast | Votes withheld** |
|------------|---|--------------------|---------------------|-------|------------------|------------------|
| 1 | Adoption of Directors' Report and Financial Statements | 3,827,705,36598.7 | 0 50,361,254 | 1.30 | 3,878,066,619 | 93,315,549 |
| 2 | Approval of the Remuneration Report | 3,641,744,37795.7 | 0 163,812,05 | 24.30 | 3,805,556,429 | 975,828,261 |
| 3 | Re-election of Sir Christopher Gent | 3,757,599,32196.9 | 0 120,406,73 | 13.10 | 3,878,006,05 | 23,377,349 |
| 4 | Re-election of Sir Andrew Witty | 3,874,304,28099.9 | 0 3,878,779 | 0.10 | 3,878,183,05 | 93,214,858 |
| 5 | Re-election of Professor Sir Roy | | | | | |
| 3 | Anderson | 3,874,110,36199.9 | | 0.10 | 3,877,898,83 | 53,482,154 |
| 6 | Re-election of Dr Stephanie Burns | 3,874,188,22099.9 | 0 3,706,042 | 0.10 | 3,877,894,26 | 23,485,110 |
| 7 | Re-election of Stacey Cartwright | 3,871,534,43799.8 | 4 6,292,248 | 0.16 | 3,877,826,68 | 53,552,308 |
| 8 | Re-election of Larry Culp | 3,863,938,36999.6 | 5 13,752,888 | 0.35 | 3,877,691,25 | 73,689,401 |
| 9 | Re-election of Sir Crispin Davis | 3,872,742,52399.8 | 7 5,082,798 | 0.13 | 3,877,825,32 | 13,554,050 |
| 10 | Re-election of Simon Dingemans | 3,873,781,08599.9 | 0 3,931,792 | 0.10 | 3,877,712,87 | 73,666,495 |
| 11 | Re-election of Judy Lewent | 3,871,977,30799.8 | 5 5,954,264 | 0.15 | 3,877,931,57 | 13,447,684 |
| 12 | Re-election of Sir Deryck Maughan | 3,865,657,28299.6 | 9 12 144 052 | 0.31 | 3 877 801 33 | 43 578 315 |
| 13 | Re-election of Dr Daniel Podolsky | | | | | |
| 14 | Re-election of Dr Moncef Slaoui | 3,873,750,72999.8 | | | 3,877,974,42 | |
| 15 | Re-election of Tom de Swaan | 3,798,800,82797.9 | , , | | | |
| 16 | Re-election of Sir Robert Wilson | 3,873,643,26599.8 | | | 3,877,890,57 | |
| 17 | Re-appointment of auditors | 3,796,598,52699.2 | | | | |
| 18 | Remuneration of auditors | 3,843,027,58999.4 | | | | |
| | Authority for the company to | , , | | | | |
| 19 | make donations to political organisations and incur political | | | | | |
| | expenditure | 3,806,217,37898.2 | | | | |
| 20 | Authority to allot shares | 3,773,307,13597.3 | 5 102,769,87 | 32.65 | 3,876,077,00 | 85,304,590 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| 21 | Disapplication of pre-emption | | | | |
|----|---------------------------------|--------------------|-------------|----------------|----------------|
| | rights*** | 3,833,012,35798.94 | 40,945,524 | 1.06 3,873,957 | 7,8817,422,017 |
| 22 | Authority for the company to | | | | |
| | purchase its own shares*** | 3,860,354,46299.55 | 17,589,398 | 0.45 3,877,943 | 3,8603,443,301 |
| 23 | Exemption from statement of | | | | |
| | senior statutory auditor's name | 3,852,410,96099.51 | 18,979,169 | 0.49 3,871,390 | 0,1299,991,468 |
| | Authorise reduced notice of a | | | | |
| 24 | general meeting other than an | | | | |
| | AGM*** | 3,521,062,64290.83 | 355,321,668 | 9.17 3,876,384 | 4,3104,998,426 |
| 25 | Renew the GSK ShareSave Plan | 3,791,116,16897.83 | 83,969,018 | 2.17 3,875,085 | 5,1866,344,467 |
| 26 | Renew the GSK ShareReward | | | | |
| | Plan | 3,832,667,50298.91 | 42,189,238 | 1.09 3,874,856 | 5,7406,574,197 |

Notes:

James Murdoch did not stand for re-election as a Director, and has stepped down from the Board with effect from noon today.

The following table provides further relevant information:

| | GlaxoSmithKline's GlaxoSmithKline' | | |
|--|------------------------------------|---------------|--|
| | Twelfth AGM | Eleventh AGM | |
| | (2012) | (2011) | |
| Issued share capital | 5,046,404,827 | 5,163,907,153 | |
| (excluding Treasury Shares) | 3,040,404,027 | 3,103,707,133 | |
| Total votes cast and votes withheld lodged as a % | | | |
| of GSK's issued share capital (excluding Treasury | 76.91% | 74.72% | |
| Shares) | | | |
| Total shareholder population | 147,408 | 155,990 | |
| Total number of proxies lodged | 9,717 | 9,886 | |
| % of shareholders who lodged proxies | 6.59% | 6.34% | |
| Number of shareholders, corporate representatives and proxies who attended the AGM | 3426 | 364 | |

V A Whyte

Company Secretary

3 May 2012

These results will shortly be available on the company's website at www.gsk.com.

GlaxoSmithKline

Enquiries:

| 1 | | | |
|---------------------|----------------|----------------------|----------|
| UK Media enquiries: | David Mawdsley | +44 (0) 20 8047 5502 | (London) |
| | Stephen Rea | +44 (0) 20 8047 5502 | (London) |
| | Sarah Spencer | +44 (0) 20 8047 5502 | (London) |
| | David Daley | +44 (0) 20 8047 5502 | (London) |

^{*} Includes discretionary votes.

^{**} A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

^{***} Indicates Special Resolutions requiring a 75% majority.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| US Media enquiries: | Kevin Colgan | +1 919 483 2839 | (North Carolina) |
|-----------------------------|--------------------|-----------------------|------------------|
| | Melinda Stubbee | +1 919 483 2839 | (North Carolina) |
| | Sarah Alspach | +1 919 483 2839 | (Washington, DC) |
| | Jennifer Armstrong | +1 919 483 2839 | (Philadelphia) |
| Analyst/Investor enquiries: | Sally Ferguson | +44 (0) 20 8047 5543 | (London) |
| onquirios. | Tom Curry | + 1 215 751 5419 | (Philadelphia) |
| | Gary Davies | + 44 (0) 20 8047 5503 | (London) |
| | Jeff McLaughlin | + 1 215 751 7002 | (Philadelphia) |
| | Ziba Shamsi | + 44 (0) 20 8047 3289 | (London) |
| | | | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: May 03, 2012

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc